The Research Progress of Bufalin in the Treatment of Hepatocellular Carcinoma.
Onco Targets Ther
; 15: 291-298, 2022.
Article
in En
| MEDLINE
| ID: mdl-35345394
ABSTRACT
Hepatocellular carcinoma (HCC) is one of the deadliest cancers in the world with a five-year survival rate of less than 20%. Nonetheless, selecting an appropriate therapeutic agent to inhibit the development of hepatoma cells is still a challenge. Bufalin, a component of the traditional Chinese medicine Chansu, has been shown to inhibit the proliferation, invasion and metastasis of HCC through various signaling pathways. In addition, bufalin and sorafenib demonstrate a synergistic effect in cancer therapeutics. This review highlighted on several focal signaling pathways involved in the inhibitory effects of bufalin on HCC and its synergistic mechanisms with sorafenib. The immunotherapy effect of bufalin has also been discussed as a novel property.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Language:
En
Journal:
Onco Targets Ther
Year:
2022
Document type:
Article